HRP20211532T1 - N-supstituirani derivati indola - Google Patents
N-supstituirani derivati indola Download PDFInfo
- Publication number
- HRP20211532T1 HRP20211532T1 HRP20211532TT HRP20211532T HRP20211532T1 HR P20211532 T1 HRP20211532 T1 HR P20211532T1 HR P20211532T T HRP20211532T T HR P20211532TT HR P20211532 T HRP20211532 T HR P20211532T HR P20211532 T1 HRP20211532 T1 HR P20211532T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- cancer
- indol
- Prior art date
Links
- -1 N-substituted indole Chemical class 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000035558 fertility Effects 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- BBRWMROCLLEJQO-UHFFFAOYSA-N 4-[6-[2-(2,7-dimethylindol-1-yl)ethylamino]pyrimidin-4-yl]benzoic acid Chemical compound CC=1N(C2=C(C=CC=C2C=1)C)CCNC1=CC(=NC=N1)C1=CC=C(C(=O)O)C=C1 BBRWMROCLLEJQO-UHFFFAOYSA-N 0.000 claims 1
- RMDMWMHGIHTDIR-UHFFFAOYSA-N 4-[6-[2-(2-bromoindol-1-yl)ethylamino]pyrimidin-4-yl]benzoic acid Chemical compound BrC=1N(C2=CC=CC=C2C=1)CCNC1=CC(=NC=N1)C1=CC=C(C(=O)O)C=C1 RMDMWMHGIHTDIR-UHFFFAOYSA-N 0.000 claims 1
- ZAIXSXCCJQKFKG-UHFFFAOYSA-N 4-[6-[2-(2-chloroindol-1-yl)ethylamino]pyrimidin-4-yl]benzoic acid Chemical compound ClC=1N(C2=CC=CC=C2C=1)CCNC1=CC(=NC=N1)C1=CC=C(C(=O)O)C=C1 ZAIXSXCCJQKFKG-UHFFFAOYSA-N 0.000 claims 1
- SXPJRHGUJPJOTF-UHFFFAOYSA-N 4-[6-[2-(2-cyanoindol-1-yl)ethylamino]pyrimidin-4-yl]benzoic acid Chemical compound C(#N)C=1N(C2=CC=CC=C2C=1)CCNC1=CC(=NC=N1)C1=CC=C(C(=O)O)C=C1 SXPJRHGUJPJOTF-UHFFFAOYSA-N 0.000 claims 1
- BTPBTZKFLVYUPZ-UHFFFAOYSA-N 4-[6-[2-(2-methylindol-1-yl)ethylamino]pyrimidin-4-yl]benzoic acid Chemical compound CC=1N(C2=CC=CC=C2C=1)CCNC1=CC(=NC=N1)C1=CC=C(C(=O)O)C=C1 BTPBTZKFLVYUPZ-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017062008 | 2017-05-18 | ||
| EP18725223.4A EP3625224B1 (en) | 2017-05-18 | 2018-05-17 | N-substituted indole derivatives |
| PCT/EP2018/062865 WO2018210995A1 (en) | 2017-05-18 | 2018-05-17 | N-substituted indole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211532T1 true HRP20211532T1 (hr) | 2022-01-07 |
Family
ID=62186481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211532TT HRP20211532T1 (hr) | 2017-05-18 | 2018-05-17 | N-supstituirani derivati indola |
Country Status (32)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| EP3625227B1 (en) | 2017-05-18 | 2022-09-14 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| AR111808A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| SI3625222T1 (sl) | 2017-05-18 | 2021-11-30 | Idorsia Pharmaceuticals Ltd | Derivati fenila kot modulatorji receptorja pge2 |
| WO2021060281A1 (ja) * | 2019-09-24 | 2021-04-01 | Ａｇｃ株式会社 | プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
| EP4245301A4 (en) | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60038902D1 (de) | 2000-03-24 | 2008-06-26 | Asterand Uk Ltd | Verwendung von prostanoid-ep4-rezeptor-antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| MXPA04009960A (es) | 2002-04-12 | 2004-12-13 | Pfizer | Compuestos de pirazol como agentes anti-inflamatorios y analgesicos. |
| AU2003216579A1 (en) | 2002-04-12 | 2003-10-27 | Pfizer Inc. | Imidazole compounds as anti-inflammatory and analgesic agents |
| AU2003233297A1 (en) | 2002-05-23 | 2003-12-12 | Theratechnologies Inc | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
| ATE396182T1 (de) | 2003-01-29 | 2008-06-15 | Asterand Uk Ltd | Hemmstoffe des ep4-rezeptors |
| CN1871240B (zh) * | 2003-08-26 | 2012-11-07 | 帝人制药株式会社 | 吡咯并嘧啶酮衍生物 |
| KR100747401B1 (ko) | 2003-09-03 | 2007-08-08 | 화이자 인코포레이티드 | 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물 |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| EP1756042B8 (en) | 2004-05-04 | 2014-06-04 | RaQualia Pharma Inc | Substituted methyl aryl or heteroaryl amide compounds |
| AP2006003769A0 (en) | 2004-05-04 | 2006-10-31 | Pfizer | Ortho substituted aryl or heteroaryl amide compounds |
| GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| WO2006122403A1 (en) | 2005-05-19 | 2006-11-23 | Merck Frosst Canada Ltd. | Quinoline derivatives as ep4 antagonists |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| US7968578B2 (en) | 2006-04-24 | 2011-06-28 | Merck Frosst Canada Ltd. | Indole amide derivatives as EP4 receptor antagonists |
| EP2035376B1 (en) | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Indoline amide derivatives as ep4 receptor ligands |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| AR061974A1 (es) | 2006-07-14 | 2008-08-10 | Novartis Ag | Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion |
| EP2054401B1 (en) | 2006-08-11 | 2013-05-01 | Merck Canada Inc. | Thiophenecarboxamide derivatives as ep4 receptor ligands |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| CN101622230B (zh) | 2007-02-26 | 2012-08-22 | 默克弗罗斯特加拿大有限公司 | 作为ep4受体拮抗剂的吲哚和二氢吲哚环丙基酰胺衍生物 |
| US8030489B2 (en) | 2007-03-26 | 2011-10-04 | Astellas Pharma Inc. | Ornithine derivative |
| CN101636385B (zh) | 2007-03-26 | 2012-09-05 | 默克弗罗斯特加拿大有限公司 | 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物 |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| WO2009005076A1 (ja) | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
| JP5375824B2 (ja) | 2008-05-14 | 2013-12-25 | アステラス製薬株式会社 | アミド化合物 |
| US8404736B2 (en) | 2008-08-14 | 2013-03-26 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as EP4 receptor antagonists |
| CN102164942B (zh) | 2008-09-19 | 2017-02-15 | 生物科技研究有限公司 | 三萜系化合物及其使用的方法 |
| EP2346866B1 (en) | 2008-09-25 | 2013-11-27 | Merck Canada Inc. | Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
| MX2012013274A (es) | 2010-05-21 | 2013-05-28 | Chemilia Ab | Novedosos derivados de la pirimidina. |
| ME02575B (me) | 2010-09-21 | 2017-06-20 | Eisai R&D Man Co Ltd | Farmaceutska kompozicija |
| CN106046158A (zh) | 2010-09-29 | 2016-10-26 | 株式会社Nb健康研究所 | 针对人前列腺素e2 受体ep4 的抗体 |
| EP2649061B1 (en) | 2010-12-10 | 2015-05-13 | Rottapharm Biotech S.r.l. | Pyridine amide derivatives as ep4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| JP5886411B2 (ja) * | 2011-03-24 | 2016-03-16 | ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ | 新規のピリミジン誘導体 |
| RU2565596C2 (ru) | 2011-07-04 | 2015-10-20 | Роттафарм Биотек С.Р.Л. | Производные циклических аминов в качестве антагонистов рецептора ер4 |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| US20150004175A1 (en) | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
| IN2014KN02601A (enExample) | 2012-04-24 | 2015-05-08 | Vertex Pharma | |
| AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| HUE039015T2 (hu) | 2013-06-12 | 2018-12-28 | Kaken Pharma Co Ltd | 4-Alkinil-imidazol-származék és ezt hatóanyagként tartalmazó gyógyszerkészítmény |
| CN105705489B (zh) | 2013-09-04 | 2019-04-26 | 百时美施贵宝公司 | 用作免疫调节剂的化合物 |
| RS57508B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,2,4-derivati oksadiazola kao imunomodulatori |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| BR112016008423B1 (pt) | 2013-10-17 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Composto, composição farmacêutica compreendendo o mesmo e seu uso |
| LT3083562T (lt) | 2013-12-17 | 2018-01-10 | Eli Lilly & Company | Fenoksietilo cikliniai amino dariniai ir jų aktyvumas kaip ep4 receptoriaus moduliatorių |
| ES2727329T3 (es) | 2013-12-17 | 2019-10-15 | Lilly Co Eli | Compuestos de ácido dimetilbenzoico |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| CA2949961C (en) | 2014-05-23 | 2023-09-19 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of cancer |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| WO2016054807A1 (en) | 2014-10-10 | 2016-04-14 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| TWI783617B (zh) | 2015-01-09 | 2022-11-11 | 日商小野藥品工業股份有限公司 | 三環性螺化合物之用途 |
| DK3325490T3 (da) | 2015-07-23 | 2020-02-03 | Takeda Pharmaceuticals Co | 1-substituerede 1,2,3,4-tetrahydro-1,7-naphthyridin-8-aminderivater og deres anvendelse som ep4-receptorantagonister |
| MX390051B (es) | 2015-10-16 | 2025-03-20 | Eisai R&D Man Co Ltd | Antagonistas de ep4. |
-
2018
- 2018-05-17 TW TW107116708A patent/TWI768043B/zh not_active IP Right Cessation
- 2018-05-17 HR HRP20211532TT patent/HRP20211532T1/hr unknown
- 2018-05-17 PH PH1/2019/502562A patent/PH12019502562B1/en unknown
- 2018-05-17 EP EP18725223.4A patent/EP3625224B1/en active Active
- 2018-05-17 HU HUE18725223A patent/HUE056406T2/hu unknown
- 2018-05-17 UA UAA201911973A patent/UA124748C2/uk unknown
- 2018-05-17 ES ES18725223T patent/ES2894124T3/es active Active
- 2018-05-17 MX MX2019013639A patent/MX394108B/es unknown
- 2018-05-17 AU AU2018269667A patent/AU2018269667B2/en not_active Ceased
- 2018-05-17 AR ARP180101311A patent/AR111806A1/es not_active Application Discontinuation
- 2018-05-17 PT PT18725223T patent/PT3625224T/pt unknown
- 2018-05-17 WO PCT/EP2018/062865 patent/WO2018210995A1/en not_active Ceased
- 2018-05-17 PE PE2019002413A patent/PE20191787A1/es unknown
- 2018-05-17 JP JP2019563494A patent/JP7065117B2/ja active Active
- 2018-05-17 DK DK18725223.4T patent/DK3625224T3/da active
- 2018-05-17 EA EA201992679A patent/EA039630B1/ru unknown
- 2018-05-17 KR KR1020197037058A patent/KR102650756B1/ko active Active
- 2018-05-17 CR CR20190567A patent/CR20190567A/es unknown
- 2018-05-17 LT LTEPPCT/EP2018/062865T patent/LT3625224T/lt unknown
- 2018-05-17 RS RS20211259A patent/RS62441B1/sr unknown
- 2018-05-17 MA MA49127A patent/MA49127B1/fr unknown
- 2018-05-17 PL PL18725223T patent/PL3625224T3/pl unknown
- 2018-05-17 CN CN201880031869.9A patent/CN110621666A/zh active Pending
- 2018-05-17 US US16/614,268 patent/US20200069686A1/en not_active Abandoned
- 2018-05-17 SG SG11201908660R patent/SG11201908660RA/en unknown
- 2018-05-17 BR BR112019024114-0A patent/BR112019024114A2/pt not_active Application Discontinuation
- 2018-05-17 CA CA3063637A patent/CA3063637A1/en active Pending
- 2018-05-17 SI SI201830413T patent/SI3625224T1/sl unknown
-
2019
- 2019-09-30 CO CONC2019/0010804A patent/CO2019010804A2/es unknown
- 2019-11-13 IL IL270616A patent/IL270616B/en unknown
- 2019-11-14 CL CL2019003257A patent/CL2019003257A1/es unknown
-
2021
- 2021-09-27 CY CY20211100841T patent/CY1124528T1/el unknown
-
2022
- 2022-11-27 US US18/058,873 patent/US20230165859A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211532T1 (hr) | N-supstituirani derivati indola | |
| JP2020520359A5 (enExample) | ||
| JP7471232B2 (ja) | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 | |
| KR102488479B1 (ko) | 인플루엔자 바이러스 감염에 사용하기 위한 인돌 | |
| JP2020143134A5 (enExample) | ||
| US9518044B2 (en) | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | |
| MX348548B (es) | Derivado heterociclico y farmaceutico. | |
| HRP20191055T1 (hr) | Terapeutska sredstva za neurodegenerativne bolesti | |
| ES2759530T3 (es) | Composición farmacéutica que contiene derivados de glutarimida, y la aplicación de la misma para el tratamiento de enfermedades eosinofílicas | |
| DE602008005582D1 (de) | Pyrazolderivate als p2x7-modulatoren | |
| CL2019001466A1 (es) | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico. | |
| JP2019513764A5 (enExample) | ||
| HRP20211429T1 (hr) | Derivati sobetiroma | |
| JP2013522292A (ja) | インダゾール化合物およびそれらの使用 | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
| JP2015524444A5 (enExample) | ||
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| JP2015510916A5 (enExample) | ||
| WO2007054770A3 (en) | Pyrazole derivatives and their medical use | |
| ES2950348T3 (es) | Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos | |
| CN111727044A (zh) | 用于治疗癌症或炎性疾病的杂二环羧酸 | |
| CN101815514B (zh) | 磺酰基取代的2-磺酰基氨基苯甲酸n-苯基酰胺在治疗疼痛中的应用 | |
| HRP20240831T1 (hr) | Derivati 1-(6-(metoksi)piridazin-3-il)ciklopropan-1-karboksamida kao modulatori autotaksina (atx) za liječenje upalnih bolesti dišnih puteva | |
| JP2015526475A5 (enExample) |